AbbVie Inc. (NYSE:ABBV) released that EC has approved marketing endorsement for IMBRUVICA (ibrutinib) for the treatment of Waldenstrom’s macroglobulinemia, a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. AbbVie said the approval […]